Structure |
Chemical Name |
CAS |
MF |
 |
Secondary Prostaglandin Metabolite LC-MS Mixture |
|
|
 |
Anti-Cyclooxygenase 3/Cox3 |
|
|
 |
(5Z,9α)-9-ヒドロキシ-11,15-ジオキソプロスタ-5-エン-1-酸 |
59894-07-4 |
C20H32O5 |
 |
(13E,15S)-9α,15-ジヒドロキシ-11-オキソプロスタ-13-エン-1-酸 |
17968-82-0 |
C20H34O5 |
 |
9-OXO-11ALPHA-15S-DIHYDROXY-PROSTA-5Z,13E-DIEN-1-OIC-3,3,4,4-D4 ACID |
34210-10-1 |
C20H28D4O5 |
 |
プロスタグランジンE1-D4 |
211105-33-8 |
C20H30D4O5 |
 |
11-Prostaglandin F2a |
|
|
 |
20-ヒドロキシ-PGE2 |
57930-95-7 |
C20H32O6 |
 |
(5Z,13E,15S)-9α,11α-エピジオキシ-15-ヒドロキシプロスタ-5,13-ジエン-1-酸 |
42935-17-1 |
C20H32O5 |
 |
(5Z,9S,11R)-9,11-ジヒドロキシ-15-オキソプロスタ-5-エン-1-酸 |
27376-76-7 |
C20H34O5 |
 |
(5Z,13E,15S)-15-ヒドロキシ-9-オキソ-5,10,13-プロスタトリエン-1-酸 |
13345-50-1 |
C20H30O4 |
 |
(5Z)-11α-ヒドロキシ-9,15-ジオキソプロスタ-5-エン-1-酸 |
363-23-5 |
C20H32O5 |
 |
Primary Prostaglandin Metabolite LC-MS Mixture |
|
|
 |
Prostaglandin F3a |
|
|
 |
8-iso Prostaglandin F2a-d4 |
|
|
 |
(5Z,13E,15R)-11α,15-ジヒドロキシ-16,16-ジメチル-9-オキソ-5,13-プロスタジエン-1-酸 |
39746-25-3 |
C22H36O5 |
 |
Prostaglandin E2-biotin |
|
C35H58N4O6S |
 |
3-アミノ-4-シクロブチル-2-ヒドロキシブタンアミド塩酸塩 (ジアステレオ異性體混合物) |
394735-23-0 |
C8H17ClN2O2 |
 |
2,3-ジクロロベンジリデンアセトアセテト |
74073-22-6 |
C12H10Cl2O3 |
 |
methyl (4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzoyl)glycinate |
864731-38-4 |
C21H17Cl2F3N2O4 |
 |
5-(2-chloroethyl)-2,3-dihydrobenzofuran |
943034-50-2 |
C10H11ClO |
![Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-, methyl ester](/CAS2/GIF/153559-48-9.gif) |
Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-, methyl ester |
153559-48-9 |
C25H30O2 |
![(3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate](/CAS/20180808/GIF/252873-35-1.gif) |
(3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate |
252873-35-1 |
C13H13NO7 |
 |
2-((TERT-ブチルトキシカルボニル)(メチル)アミノ)酢酸(2-(メチルアミノ)ピリジン-3-イル)メチル |
1180002-01-0 |
C15H23N3O4 |
 |
Fluvis group intermediate |
|
|
 |
Isavuconazole Impurity |
338990-63-9 |
C40H43ClF2N8O7S |
 |
Eribulin intermediateB |
|
|
 |
6-クロロ-2,3,4,5-テトラヒドロ-7,8-ジメトキシ-1-(4-メトキシフェニル)-1H-3-ベンゾアゼピン |
67287-53-0 |
C19H22ClNO3 |
 |
METHYL ESTER, 4,5-BIS(2-METHOXYETHOXY)-2-NITROBENZOIC ACID |
501684-22-6 |
C14H19NO8 |
![(7R,8R,9S,13S,14S,17S)-13-メチル-7-(9-((4,4,5,5,5-ペンタフルオロペンチル)チオ)ノニル)-7,8,9,11,12,13,14,15,16,17-デカヒドロ-6H-シクロペンタ[A]フェナントレン-3,17-ジオール](/CAS2/GIF/153004-31-0.gif) |
(7R,8R,9S,13S,14S,17S)-13-メチル-7-(9-((4,4,5,5,5-ペンタフルオロペンチル)チオ)ノニル)-7,8,9,11,12,13,14,15,16,17-デカヒドロ-6H-シクロペンタ[A]フェナントレン-3,17-ジオール |
153004-31-0 |
C32H47F5O2S |
 |
(2R,3R)-2-メチル-3-ヒドロキシ-3-(2,5-ジフルオロフェニル)-4-(1H-1,2,4-トリアゾール-1-イル)ブタン酸 |
483340-19-8 |
C13H13F2N3O3 |
 |
Derivatives intermediate 2 |
1213710-57-6 |
C26H38N2O3 |
 |
Pluronic PE 4300 |
|
|
 |
Entecavir hydrate |
|
|
 |
2-(2-ヒドロキシフェニル)-4H-1,3-ベンゾオキサジン-4-オン |
1218-69-5 |
C14H9NO3 |
 |
Olmesartan intermediate |
|
|
![(1R,2S)-2-[(フェニルメトキシ)メチル]-3-シクロペンテン-1-オール](/CAS/GIF/188399-48-6.gif) |
(1R,2S)-2-[(フェニルメトキシ)メチル]-3-シクロペンテン-1-オール |
188399-48-6 |
C13H16O2 |
 |
(S)-2-(((3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)methyl)-3-phenylpropanoic acid methyl ester hydrochloride |
170098-28-9 |
C24H31NO3.HCl |
 |
((2R,3S)-2-(2,5-ジフルオロフェニル)-5-ヒドロキシテトラヒドロ-2H-ピラン-3-イル)カルバミン酸TERT-ブチル |
1172623-99-2 |
C16H21F2NO4 |
 |
,100kg |
180048-73-1 |
C11H14O4S |
![4-[5-(3,5-ジクロロフェニル)-5-(トリフルオロメチル)-4,5-ジヒドロイソオキサゾール-3-イル]-2-メチル安息香酸](/CAS/20180529/GIF/864725-62-2.gif) |
4-[5-(3,5-ジクロロフェニル)-5-(トリフルオロメチル)-4,5-ジヒドロイソオキサゾール-3-イル]-2-メチル安息香酸 |
864725-62-2 |
C18H12Cl2F3NO3 |
 |
Ozagrel sodium |
130952-46-4 |
C13H13N2NaO2 |
![(2S,5R)-6-(tert-butyldimethylsilyloxy)-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide](/CAS/20210305/GIF/2209874-02-0.gif) |
(2S,5R)-6-(tert-butyldimethylsilyloxy)-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide |
2209874-02-0 |
C14H25N3O3Si |
![1,6-Diazabicyclo[3.2.1]oct-3-ene-2-carboxamide, 6-hydroxy-3-methyl-7-oxo-, (1R,2S,5R)-](/CAS/20210305/GIF/2209874-17-7.gif) |
1,6-Diazabicyclo[3.2.1]oct-3-ene-2-carboxamide, 6-hydroxy-3-methyl-7-oxo-, (1R,2S,5R)- |
2209874-17-7 |
C8H11N3O3 |
![2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile](/CAS/20180531/GIF/1187594-13-3.gif) |
2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile |
1187594-13-3 |
C22H31N7O3SSi |
 |
Derivatives intermediate 3 |
1213710-50-9 |
C21H30N2O |
 |
(2S,3R)-2-amino-3-methylpent-4-enamide |
2209873-96-9 |
C6H12N2O |
![(1α,5α)-2α-(ベンジルオキシメチル)-6-オキサビシクロ[3.1.0]ヘキサン-3β-オール](/CAS/GIF/117641-39-1.gif) |
(1α,5α)-2α-(ベンジルオキシメチル)-6-オキサビシクロ[3.1.0]ヘキサン-3β-オール |
117641-39-1 |
C13H16O3 |
 |
(S)-1-(2-(1-aMino-2-Methylpropan-2-ylaMino)acetyl)pyrrolidine-2-carbonitrile dihydrochloride (AMino pyrrolidine) |
739364-93-3 |
C11H22Cl2N4O |
![(4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate](/CAS/20200331/GIF/1187595-90-9.gif) |
(4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate |
1187595-90-9 |
C22H27N7O4S |
 |
Danshen injection intermediate |
|
|
 |
Flomoxef Intermediate FXMT |
|
|
![Oxaliplatin System Suitability ([SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine-N,N') dichloridoplatinum(II))](/CAS/20180713/GIF/61848-66-6.gif) |
Oxaliplatin System Suitability ([SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine-N,N') dichloridoplatinum(II)) |
61848-66-6 |
C6H12Cl2N2Pt |
![(3R,3αS,6αR)-Hydroxyhexa-hydrofuro[2,3-β]furan-3-yl acetate](/CAS/20180808/GIF/186488-43-7.gif) |
(3R,3αS,6αR)-Hydroxyhexa-hydrofuro[2,3-β]furan-3-yl acetate |
186488-43-7 |
C8H12O4 |
![(2E,4R)-4-[(1R,3aS,4E,7aR)-4-[(2E)-2-[(3S,5R)-3,5-Bis[[(tert-butyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-cyclopropyl-2-penten-1-one](/CAS/GIF/112849-17-9.gif) |
(2E,4R)-4-[(1R,3aS,4E,7aR)-4-[(2E)-2-[(3S,5R)-3,5-Bis[[(tert-butyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-cyclopropyl-2-penten-1-one |
112849-17-9 |
C39H66O3Si2 |
![1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate](/CAS/20180629/GIF/864686-28-2.gif) |
1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate |
864686-28-2 |
C28H33N3O2 |
![(1S,5R)-1-(3-フルオロフェニル)-3-オキサビシクロ[3.1.0]ヘキサン-2-オン](/CAS/20200119/GIF/528587-70-4.gif) |
(1S,5R)-1-(3-フルオロフェニル)-3-オキサビシクロ[3.1.0]ヘキサン-2-オン |
528587-70-4 |
C11H9FO2 |
 |
Larotaxel intermediate(A-3) |
156294-33-6 |
C31H36O10 |
 |
Flomoxef Intermediate OXA |
|
|
 |
Pantoprazole Sodium Intermediates |
|
|
 |
Ethyl 6,7-difluoro-2-ethylmercapto-4-hydroxyquinoline-3-carboxylate |
154330-67-3 |
C14H13F2NO3S |
 |
Nevirapine intermediate |
|
|
 |
1,4-bis(4-chloro-2-fluoro-5-nitrophenyl)butane-1,4-dione |
1292836-19-1 |
C16H8Cl2F2N2O6 |
 |
Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-, compd. with (R)-alpha-methylbenzenemethanamine (1:1), monohydrate (9CI) |
65794-75-4 |
C11H18NO4P |
 |
Canagliflozin Intermediate epimers |
|
|
 |
(S,Z)-5-Amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one |
156732-13-7 |
C32H32N2O |
 |
6-(4-クロロフェニル)-2,2-ジメチル-7-フェニル-2,3-ジヒドロ-1H-ピロリジン |
133111-56-5 |
C21H20ClN |
![CarbaMic acid, [(1S)-3-Methyl-1-(2-Methylpropyl)-2-oxo-3-butenyl]-, 1,1-diMethylethyl ester (9CI)](/CAS/20150408/GIF/247068-81-1.gif) |
CarbaMic acid, [(1S)-3-Methyl-1-(2-Methylpropyl)-2-oxo-3-butenyl]-, 1,1-diMethylethyl ester (9CI) |
247068-81-1 |
C14H25NO3 |
 |
Lixivaptan intermediate-IV |
179063-21-9 |
C19H14ClN3O3 |
 |
Sugammadex sodium 7-Bromide intermediates |
|
|
 |
Remdesivir No. 5 intermediate |
|
|
 |
(5R)-2,2-ジオキシド-5-メチル-1,2,3-オキサチアゾリジン, N-BOC保護(hù) |
863453-61-6 |
C8H15NO5S |
 |
Flomoxef Intermediate KDFA |
|
|
![5-(Difluoromethoxy)-2[[(4-chloro-3-methoxy-2-pyridinyl)methyl]-thio]-1H-benzimidazole](/CAS/GIF/368890-20-4.gif) |
5-(Difluoromethoxy)-2[[(4-chloro-3-methoxy-2-pyridinyl)methyl]-thio]-1H-benzimidazole |
368890-20-4 |
C15H12ClF2N3O2S |
![4a,5,9,10,11,12-hexahydro-1-bromo-3-methoxy-11-formyl-6H-benzofuro[3a,3,2-ef
][2]benzazepin-6-one](/CAS/GIF/122584-14-9.gif) |
4a,5,9,10,11,12-hexahydro-1-bromo-3-methoxy-11-formyl-6H-benzofuro[3a,3,2-ef
][2]benzazepin-6-one |
122584-14-9 |
C17H16BrNO4 |
 |
Pemetrexed intermediate |
|
|
 |
1,2,4-butanetriol-3-(1,4,7,10-tetraazacyclododec-1-yl)4hydrochloride |
156077-56-4 |
C12H29ClN4O3 |
 |
2-イソプロポキシ-5-メチル-4-(ピペリジン-4-イル)アニリン二塩酸塩水和物 |
1802250-63-0 |
C15H27ClN2O2 |
 |
-- |
93360-08-8 |
C30H27N2O6P |
 |
(S)-3-Cyano-5-methylhexanoic acid ethyl ester |
181289-39-4 |
C10H17NO2 |
![5,7-ジオキサ-6-チアスピロ[2.5]オクタン6-オキシド](/CAS/GIF/89729-09-9.gif) |
5,7-ジオキサ-6-チアスピロ[2.5]オクタン6-オキシド |
89729-09-9 |
C5H8O3S |
![5-(4-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-hexanoic acid ethyl ester](/CAS/GIF/147125-14-2.gif) |
5-(4-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-hexanoic acid ethyl ester |
147125-14-2 |
C33H56O3Si |
 |
Sterolazole intermediate |
|
|
 |
Lixivaptan intermediate-V |
168079-19-4 |
C19H16ClN3O |
 |
((1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-5,6-dimethyl-6-(trimethylsilyloxy)hept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diyl)bis(oxy)bis(tert-butyldimethylsilane) |
2186604-89-5 |
C42H80O3Si3 |
 |
Carbamazepine intermediate |
|
|
![3-(1,1-diMethylethyl)-7a-ethenyltetrahydro-1-hydroxy-(3R,7aR)-3H,5H-Pyrrolo[1,2-c]oxazol-5-one](/CAS/GIF/1214741-21-5.gif) |
3-(1,1-diMethylethyl)-7a-ethenyltetrahydro-1-hydroxy-(3R,7aR)-3H,5H-Pyrrolo[1,2-c]oxazol-5-one |
1214741-21-5 |
C12H19NO3 |
 |
Cabazitaxel N-3 |
859498-31-0 |
C57H61Cl6NO19 |
 |
tetramethyl 3,3',3'',3'''-(porphyrin-5,10,15,20-tetrayl)tetrabenzoate |
75286-83-8 |
C52H38N4O8 |
 |
Dabigatran intermediate |
|
|
![(7alpha,17beta)-17-(Acetyloxy)-7-[9-[(4,4,5,5,5-pentafluoropentyl)thio]nonyl]estr-4-en-3-one](/CAS/20150408/GIF/415927-29-6.gif) |
(7alpha,17beta)-17-(Acetyloxy)-7-[9-[(4,4,5,5,5-pentafluoropentyl)thio]nonyl]estr-4-en-3-one |
415927-29-6 |
C34H51F5O3S |
 |
Engelide intermediate |
|
|
 |
Material intermediate |
162039-67-0 |
C18H14N4 |
![2-[3-オキソ-5-(2,3-ジヒドロ-1H-ペリミジン-2-イル)-6-ヒドロキシ-3H-キサンテン-9-イル]安息香酸](/CAS/GIF/80474-45-9.gif) |
2-[3-オキソ-5-(2,3-ジヒドロ-1H-ペリミジン-2-イル)-6-ヒドロキシ-3H-キサンテン-9-イル]安息香酸 |
80474-45-9 |
C24H30F2O5S |
 |
Dolutegravir intermediate |
|
|
![4-[3-(トリフルオロメチル)フェニル]-1-ピペラジンエタノール](/CAS/GIF/40004-29-3.gif) |
4-[3-(トリフルオロメチル)フェニル]-1-ピペラジンエタノール |
40004-29-3 |
C13H17F3N2O |
![(4AS,7AS)-オクタヒドロピロロ[3,4-B][1,4]オキサジン](/CAS/20150408/GIF/209401-69-4.gif) |
(4AS,7AS)-オクタヒドロピロロ[3,4-B][1,4]オキサジン |
209401-69-4 |
C6H12N2O |
 |
Eribulin intermediate |
157322-47-9 |
C21H35IO4 |
 |
Flomoxef Intermediate F3-01 |
|
|
![5-Pyrimidineacetamide, 2-butyl-1-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1,6-dihydro-N,N,4-trimethyl-6-oxo-](/CAS/20210111/GIF/1985668-78-7.gif) |
5-Pyrimidineacetamide, 2-butyl-1-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1,6-dihydro-N,N,4-trimethyl-6-oxo- |
1985668-78-7 |
C27H30N4O2 |